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Purpose Intra-articular corticosteroid injection (IACI) with triamcinolone hexacetonide (TH) is a mainstay of therapy for patients with juvenile idiopathic arthritis (JIA). Our aim was to determine factors that affected the durability of response to IACI with TH in patients with JIA.
Methods
A retrospective chart review was conducted of all JIA patients who received IACI from 6/05 to 3/10, and had at least six months of follow-up. Data collected included demographic information, JIA subtype, date of injection and arthritis flare, type of joint injected and concomitant medications. Any joint that did not flare by the study end date in 9/10 was censored. Time to flare of arthritis was calculated based on the Kaplan-Meier product limit estimator. Two-sided log-rank test was conducted to compare the time to flare within each characteristic group: joints, diagnosis, medications. All analysis in this study was performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
Results
There were 112 patients (83 females) and 198 separate joints included in the study. Fourteen (7.1%) joints did not respond to their first IACI. Of the 184 joints that did respond to the initial IACI, 99 (53.8%) fully improved and did not relapse during the study period (duration of follow-up: mean 723.7 ±421 days; median 553 days, IQR 385-994). There was a significant differ-ence in time to flare between elbow and wrist joints. Although hip joints showed the shortest time to flare, the sample size was too small to tell if the difference was significant.
Twenty to 36% of each joint type received a second IACI. About a third of the re-injected knee joints required a third IACI, and all four of the re-injected hip joints received a third IACI.
Conclusion
IACI is an effective therapy for patients with JIA with the majority of patients having complete and long-lasting response to IACI. Over half of the injected joints did not relapse after a mean and median follow up of 23.7 months and 18.2 months, respectively. There was a significant difference in median time to flare between the elbow and wrist joints. Knees had the longest median time to relapse and hips the shortest; however, a larger sample is needed to determine if these represent significant differences. Systemic arthritis showed the shortest time to relapse, and was statistically different from oligoarthritis and polyarthritis. Concomitant medications did not have a significant effect on flare times. A larger study population is needed to better evaluate the effect of joint type and other factors on risk of recurrent flares. 
